A new study suggests that a simple blood test could identify women at high risk of developing dementia up to 25 years before symptoms appear. Researchers at the University of California, San Diego, found a strong link between elevated levels of the protein plasma phosphorylated tau 217 (p-tau217) in blood samples and the subsequent development of mild cognitive impairment (MCI) or dementia. The findings, published in the Journal of the American Medical Association, highlight the potential for early detection, but also reveal complexities in how this biomarker performs across different populations.
Key Findings of the Study
The study followed 2,766 women aged 65 to 79 over two decades (1996–2021). Over that time, 1,311 developed either MCI or dementia. Women with higher baseline p-tau217 levels were significantly more likely to be diagnosed with these conditions. This suggests p-tau217 could serve as an early warning signal for the disease.
However, the association was stronger in women taking combined estrogen and progestin hormone therapy compared to those on a placebo. The estrogen-only group did not show the same heightened risk. Additionally, the test proved more accurate in women over 70 and those carrying the APOE ε4 gene, a known genetic risk factor for Alzheimer’s disease.
Why This Matters
Alzheimer’s disease and other forms of dementia are progressive, irreversible conditions. Detecting risk factors early could allow individuals to make lifestyle changes, engage in clinical trials, or prepare for the future. The study’s lead author, Aladdin H. Shadyab, explained that the blood test could “identify individuals at higher risk for dementia long before symptoms begin.”
This is significant because current diagnostic methods (cognitive tests, brain scans) are often used after symptoms have emerged, when interventions may be less effective. A simple blood test offers a potentially accessible and cost-effective screening tool.
Limitations and Future Directions
The study acknowledges several limitations. The sample consisted solely of older women, meaning the findings may not apply to men or younger individuals. Additionally, the test’s predictive power varied across racial groups: it was less accurate in Black women than in white women.
Ian McDonough, a researcher not involved in the study, noted that “plasma biomarkers are not going to be a one-size-fits-all forecasting solution.” Further research is needed to refine the test and ensure its reliability across diverse populations.
Beyond Biomarkers: Lifestyle and Early Signs
While blood tests may help identify risk, experts emphasize that lifestyle factors play a crucial role in dementia prevention. Regular physical and mental activity, along with a healthy diet, can reduce risk. Recognizing early symptoms – such as short-term memory loss, personality changes, and difficulty with word-finding or planning – is also essential.
Ultimately, proactive health management, coupled with advances in early detection, offers the best approach to confronting the growing challenge of dementia.
